Therapeutic Asset Ratings
172 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Bryostatin 1
Multiple Sclerosis
Robert Fox
P1
C
(37)
Fludarabine Phosphate For
Multiple Sclerosis
St. Petersburg State Pavlov Medical University
P1
C
(37)
Foralumab
Multiple Sclerosis
Tiziana Life Sciences LTD
P1
C
(37)
Glibenclamide
Multiple Sclerosis
University of Maryland, Baltimore
P1
C
(37)
Idp-023
Multiple Sclerosis
Indapta Therapeutics, INC.
P1
C
(37)
ims001
Multiple Sclerosis
ImStem Biotechnology
P1
C
(37)
Intranasal Foralumab
Multiple Sclerosis
Tiziana Life Sciences LTD
P1
C
(37)
Ipilimumab
Multiple Sclerosis
National Cancer Institute (NCI)
P1
C
(37)
ivl3004
Multiple Sclerosis
Inventage Lab., Inc.
P1
C
(37)
ivl4002
Multiple Sclerosis
Inventage Lab., Inc.
P1
C
(37)
Kite-363
Multiple Sclerosis
Kite, A Gilead Company
P1
C
(37)
Lu Ag06466
Multiple Sclerosis
H. Lundbeck A/S
P1
C
(37)
Nivolumab
Multiple Sclerosis
National Cancer Institute (NCI)
P1
C
(37)
Ocrelizumab Co-Formulated With Rhuph20
Multiple Sclerosis
Hoffmann-La Roche
P1
C
(37)
Orca-Q
Multiple Sclerosis
Stanford University
P1
C
(37)
P-Cd19Cd20-Allo1 Cells
Multiple Sclerosis
Genentech, Inc.
P1
C
(37)
RO7121932
Multiple Sclerosis
Hoffmann-La Roche
P1
C
(37)
Rph-035
Multiple Sclerosis
R-Pharm
P1
C
(37)
s103 cells
Multiple Sclerosis
Xijing Hospital
P1
C
(37)
Thiotepa
Multiple Sclerosis
Stanford University
P1
C
(37)
Vancomycin
Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
P1
C
(37)
Zirconium Zr 89 Crefmirlimab Berdoxam
Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS)
P1
C
(37)
ad26.cov2.s
Multiple Sclerosis
Griffin Hospital
Early P1
C
(34)
ct103a cells
Multiple Sclerosis
Tongji Hospital
Early P1
C
(34)
Gentamycin
Multiple Sclerosis
Medstar Health Research Institute
Early P1
C
(34)
Showing 126 to 150 of 172 assets
Previous
Page 6 of 7
Next